´ëÇѼÒȱâ¾Ï¿¬±¸ÇÐȸ Á¦19ȸ Ãá°èÇмú´ëȸ : 2024-03-30
±³À°ÀÏÀÚ : 2024-03-30
±³À°Àå¼Ò : ½ºÀ§½º±×·£µå
±³À°ÁÖÁ¦ : ´ëÇѼÒȱâ¾Ï¿¬±¸ÇÐȸ Á¦19ȸ Ãá°èÇмú´ëȸ
ÁÖÃÖ±â°ü : ´ëÇѼÒȱâÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇѼÒȱâ¾Ï¿¬±¸ÇÐȸ
´ã´çÀÚ : ÀÌÇѳª
¿¬¶ôó : 02-313-7710
À̸ÞÀÏ : gicancer@gicancer.or.kr
±³À°Á¾·ù : ³»°ú, ÀÇ·áÀ±¸®ÇÐ
Âü¼®¿¹»óÀÎ : 100¸í
Èñ¸ÁÆòÁ¡ : 6Á¡ (ÀÏ¹Ý 5Á¡ / Çʼö 1Á¡)
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 13 ½Ã°£ 30ºÐ
¼¼ºÎ¼ö°·á : 100,000¿ø
ºñ°í "±¸ºÐ »çÀüµî·Ï ÇöÀåµî·Ï
Àü¹®ÀÇ(±³¼ö, ºÀÁ÷ÀÇ, °³¿øÀÇ µî) 5¸¸¿ø 7¸¸¿ø
Àü°øÀÇ, ÀüÀÓÀÇ, ÀϹÝÀÇ ¹«·á 5¸¸¿ø
Çлý, ÀÇ»ç ¿Ü ±âŸÁ÷±º ¹«·á 5¸¸¿ø
ÁÂÀå, ¿¬ÀÚ, ÇмúÀ§¿ø ¹«·á ¹«·á
¸¸65¼¼ ÀÌ»ó Æò»ýȸ¿ø ¹«·á ¹«·á
ºñȸ¿ø(À¯·á) 8¸¸¿ø 10¸¸¿ø"
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 03¿ù 30ÀÏ Lobby 08:30~09:00 µî·Ï ()
±âŸ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall A, B 09:00~09:10 °³È¸»ç ()
±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall A 09:10~09:35 Esophageal/Stomach Cancer ¹ÚÀçÈ£(Ãæ³²ÀÇ´ë)
±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall A 09:35~10:00 Colorectal Cancer ±èµ¿¿ì(°í·ÁÀÇ´ë)
±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall A 10:00~10:25 Pancreatobiliary Cancer Á¶ÁßÇö(¿¬¼¼ÀÇ´ë)
ÈÞ½Ä 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall A, Lobby 10:25~10:40 ()
±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall A 10:40~11:05 Optimizing Treatment for Oligometastatic Advanced Gastric Cancer: Gastroenterologist¡¯s View (KSGC) ÀüÇÑÁ¶(°í·ÁÀÇ´ë)
±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall A 11:05~11:30 Optimizing Treatment for Oligometastatic Advanced Gastric Cancer: Surgeon¡¯s View (IASGO) Koichi Hayano(Chiba Univ., Japan)
±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall A 11:30~11:55 Gastric Outlet Obstruction in Patients with Pancreatobiliary Cancer: Endoscopic Treatment (KSGC) À嵿±â(¼¿ïÀÇ´ë)
±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall A 11:55~12:20 Gastric Outlet Obstruction in Patients with Pancreatobiliary Cancer: Surgical Treatment (IASGO) Yosuke Kasai(Kyoto Univ., Japan)
±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall A, B 12:20~12:50 Durvalumab: Real-World Practice in Advanced Biliary Tract Cancer ¹é¿ìÇö(¼¿ïÀÇ´ë)
±âŸ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall A, B 12:50~13:20 ´ëÇѼÒȱâ¾Ï¿¬±¸ÇÐȸ ÃÑȸ ()
±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall A 13:20~13:45 Neoadjuvant and Adjuvant Therapy for Cholangiocarcinoma ÀÌÀç¹Î(°í·ÁÀÇ´ë)
±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall A 13:45~14:10 Surgical Approaches for Cholangiocarcinoma À±À¯¼®(¼¿ïÀÇ´ë ¿Ü°ú)
±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall A 14:10~14:35 Therapeutic Approaches in Palliative Care for Cholangiocarcinoma ÀüÁß¿ø(±¹¸³¾Ï¼¾ÅÍ)
±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall A 14:35~15:00 Advances in Targeted Therapies and Immunotherapy for Cholangiocarcinoma Á¤¹®Àç(¿¬¼¼ÀÇ´ë)
ÈÞ½Ä 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall A, Lobby 15:00~15:20 Coffee Break ()
±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall A 15:20~15:30 Real-world evidence of FOLFIRINOX as a first-line salvage treatment in primary chemotherapy-refractory biliary tract cancer ±èÁöÈÆ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall A 15:30~15:40 Nivolumab versus Pembrolizumab Comparative efficacy of Nivolumab and Pembrolizumab as Palliative therapies in Biliary tract cancer ÀÌŽÂ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall A 15:40~15:50 Efficacy of third-line palliative chemotherapy in patients with advanced pancreatic cancer ±èÀçȯ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall A 15:50~16:00 Significance of reproductive factors as predictors of high risk for developing gallbladder cancer in Korean women with benign gallbladder disease ÀÌ¿ë¿ì(°æºÏÀÇ´ë)
±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall A 16:00~16:10 Comparison of Endoscopic Ultrasound-Guided Tissue Acquisition for Solid Liver Masses: Menghini Needle with a Lateral Forward Bevel vs. Franseen Needle À̽ÿµ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall A 16:10~16:20 Proportional Correlation Between Systemic Inflammation Response Index and Time to Gastric Cancer Recurrence Àΰæ·û(Ãæ³²ÀÇ´ë)
±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall A 16:20~16:30 An Inverse Association Between Dietary ¥â-Carotene And Vitamin A Intake And Colorectal Adenoma Incidence: A Cross-Sectional Study and Meta-analysis Á¤ÁÖ¿ø(À»ÁöÀÇ´ë)
±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall A 16:30~16:40 Comparison of the prognosis and lymph node metastasis between ¡°no tumor budding¡± and ¡°low-grade tumor budding¡± in T1 and T2 colorectal cancer ÀÌÁ¾À±(µ¿¾ÆÀÇ´ë)
±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall A 16:40~16:50 Distinct Microbiome Composition and Network Formation in Saliva, Feces, and Blood of Patients with Pancreatic Cancer ±èÀçȯ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall A 16:50~17:00 Oral Microbiome Signatures Enable Non‑Invasive Diagnosis of Pancreatic Ductal Adenocarcinoma in Korean Patients ±èÁöÈÆ(¿¬¼¼ÀÇ´ë)
±âŸ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall A 17:00~17:10 ½Ã»ó½Ä ()
±âŸ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall A 17:10~17:20 Æóȸ»ç ()
±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall B 09:10~09:35 Macrophage-Derived WNT Signaling: Orchestrating Immune Suppression and Progression in Pancreatic Cancer ¼®½ÂÇõ(¼¿ï´ë ¹Ì»ý¹°Çаú)
±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall B 09:35~10:00 Transforming DNA Data into Action with Whole Genome Insights °íÁØ¿µ(Áö³ðÀλçÀÌÆ®)
±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall B 10:00~10:25 Novel Drug Delivery Mechanism by Utilizing Stemsomes for Targeting Pancreatic Cancer °µ¿¿ì(°¡Ãµ´ë »ý¸®Çаú)
ÈÞ½Ä 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall B, Lobby 10:25~10:40 ()
±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall B 10:40~11:05 Investigating the Relationship with MRI-based Radiomics and Next-Generation Sequencing Using Rim Enhancement of Pancreatic Ductal Adenocarcinoma À±½Â¹è(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall B 11:05~11:30 Comparative Efficacy of 5-Fluorouracil and Capecitabine as Adjuvant Therapies in Biliary Tract Cancer: A Comprehensive Analysis of Outcomes ÀÌŽÂ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall B 11:30~11:55 Survival Predictors in Pancreatic Cancer Patients on Liposomal Irinotecan Plus Fluorouracil/Leucovorin ±ÝÁö¿µ(ÀÌÈÀÇ´ë)
±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall B 11:55~12:20 A Novel Retractable Robotic Device for Colorectal Endoscopic Submucosal Dissection ±è»óÇö(°í·ÁÀÇ´ë)
±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall A, B 12:20~12:50 Durvalumab: Real-World Practice in Advanced Biliary Tract Cancer ¹é¿ìÇö(¼¿ïÀÇ´ë)
±âŸ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall A, B 12:50~13:20 ´ëÇѼÒȱâ¾Ï¿¬±¸ÇÐȸ ÃÑȸ ()
±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall B 13:20~13:45 Nivolumab for Gastric Cancer: Real-World Practice °¼±Çü(Ãæ³²ÀÇ´ë)
±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall B 13:45~14:10 Novel Therapies in HER2-Positive Gastric Cancer °¹öµé(Â÷ÀÇ°úÇдë Á¾¾ç³»°ú)
±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall B 14:10~14:35 Recent Updates in Neoadjuvant Treatment for Colon Cancer ÀÌÁ¾À±(µ¿¾ÆÀÇ´ë)
±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall B 14:35~15:00 Patient Selection and Treatment Delivery Aiming for Organ Preservation in Rectal Cancer ±èÁø¾Æ(¿¬¼¼ÀÇ´ë ¹æ»ç¼±Á¾¾çÇаú)
ÈÞ½Ä 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall B, Lobby 15:00~15:20 Coffee Break ()
±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall B 15:20~15:55 µðÁöÅÐ ÀÇ·á±â¼ú¿¡¼ÀÇ À±¸®Àû ÀïÁ¡ ±èÁØÇõ(¿¬¼¼´ëÇб³ Ä¡°ú´ëÇÐ) Çʼö
±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall B 15:55~16:30 ÀÇÇבּ¸À±¸®¿Í ÀÌÇØ»óÃæ ÀÌÀÏÇÐ(¿¬¼¼´ëÇб³ ÀÇ·á¹ýÀ±¸®Çаú) Çʼö
±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall B 16:30~17:00 Æø¾ð ¹× ³ìÃë, ÆøÇà°ü·Ã ÀÇ»çÀÇ ´ëó¿¡¼ÀÇ ÀÇ·áÀ±¸®ÀÇ ¿ªÇÒ ¹ÚÁö¿ë(¿¬¼¼´ëÇб³ ¹ýÇдëÇÐ) Çʼö
±âŸ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall B 17:00~17:10 ½Ã»ó½Ä ()
±âŸ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall B 17:10~17:20 Æóȸ»ç ()